Form 4: Beam Therapeutics CFO Receives Stock Options and Restricted Stock Units
SEC Form 4 Filing
Terry-Ann Burrell, CFO of Beam Therapeutics, reports the acquisition of stock options and restricted stock units.
Summary
- Terry-Ann Burrell, the Chief Financial Officer of Beam Therapeutics Inc. (BEAM), filed a Form 4 on April 29, 2024, reporting changes in beneficial ownership.
- On April 26, 2024, Burrell acquired 12,500 restricted stock units (RSUs) and 25,000 stock options.
- The RSUs vest in three equal annual installments starting September 30, 2024.
- The stock options vest in equal monthly installments following July 31, 2023, over the subsequent thirty-six months.
- The exercise price for the stock options is $30.87.
- Following these transactions, Burrell directly owns 82,637 shares of Beam Therapeutics common stock and 25,000 stock options.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive as it reflects standard executive compensation practices, incentivizing management and aligning their interests with shareholders.
Positives
- The grant of RSUs and stock options to the CFO aligns her interests with those of the shareholders.
- Vesting schedules incentivize continued service with the company.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedules of the RSUs and stock options.
Industry Context
Stock option and RSU grants are common compensation practices in the biotechnology industry to attract and retain key executives.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry, similar to companies like CRISPR Therapeutics and Editas Medicine.
- The vesting schedules are typical, aligning with industry norms for incentivizing long-term performance.
Stakeholder Impact
- Shareholders may view the grants positively as they incentivize the CFO to improve company performance.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| July 31, 2023 | Start date for monthly vesting of stock options. |
| September 30, 2023 | Base date for RSU vesting anniversary. |
| April 26, 2024 | Date of transaction: acquisition of RSUs and stock options. |
| April 29, 2024 | Date of Form 4 filing. |
| September 30, 2024 | First anniversary of base date for RSU vesting. |
| April 26, 2034 | Expiration date of stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.